FRLN实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (17 Feb 2024 @ 04:37):

Stats
今日成交量	5 349.00
平均成交量	28 144.00
市值	28.28M
EPS	$0 ( 2024-04-02 )
下一个收益日期	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.569
ATR14	$0.0640 (0.99%)

音量相关性

長: -0.38 (neutral)

短: 0.00 (neutral)

Signal:(61.011) Neutral

Freeline Therapeutics 相关性

10 最正相关
INVZ	0.906
VEEE	0.895
PSTV	0.891
ISUN	0.891
COMM	0.889
MTCH	0.887
DIBS	0.886
BBIG	0.884
ICCC	0.879
NEGG	0.877

10 最负相关
TYHT	-0.846
RAM	-0.825
SVFC	-0.82
CPTA	-0.816
ALDX	-0.807
SCR	-0.804
VERX	-0.803
EBSB	-0.803
AAON	-0.802
BLCT	-0.801

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Freeline Therapeutics 相关性 - 货币/商品

-0.79
( moderate negative )

-0.74
( moderate negative )

0.00
( neutral )

-0.71
( moderate negative )

-0.15
( neutral )

0.72
( moderate )

Freeline Therapeutics 财务报表

Annual	2022
营收:	$0
毛利润:	$-1.74M (0.00 %)
EPS:	$-22.52

FY	2022
营收:	$0
毛利润:	$-1.74M (0.00 %)
EPS:	$-22.52

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-3.93

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-6.81

Financial Reports:

No articles found.

Freeline Therapeutics

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.